Clinical Pharmacotherapy for PTSD: Single and Collaborative Studies (R34)

The summary for the Clinical Pharmacotherapy for PTSD: Single and Collaborative Studies (R34) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Clinical Pharmacotherapy for PTSD: Single and Collaborative Studies (R34): -Purpose. The sponsoring agencies jointly issue this Funding Opportunity Announcement (FOA) to stimulate research grant applications focused on pharmacological treatments for Post-Traumatic Stress Disorder (PTSD). Medications along a continuum of development and testing (i.e., exploratory compounds ready for human testing, medications used in other areas of medicine and thought to be useful for a new indication (PTSD), and psychiatric medications currently used off-label to treat PTSD) are appropriate as the focus of a research grant application in response to this FOA. The sponsoring agencies seek to advance PTSD pharmacotherapy research by providing resources to better understand feasibility, tolerability, acceptance, safety, possible efficacy and risk/benefit ratios pertaining to symptoms and symptom severity, side effects, and treatment gains in functioning associated with available and novel medications. The sponsoring agencies anticipate the results of such studies will help identify potential medications suitable for larger scale efficacy, effectiveness and services research studies. -Mechanism of Support. This FOA will utilize the NIMH R34 award mechanism and includes an option of collaborative R34 applications if two sites will participate. -Funds Available and Anticipated Number of Awards. The NIMH intends to commit approximately $2,000,000 in Fiscal Year 2009 to fund 5 to 8 grants submitted in response to this FOA. The VA Office of Research and Development, depending upon availability of funds, estimates committing up to $2,000,000 for this initiative.

Federal Grant Title:	Clinical Pharmacotherapy for PTSD: Single and Collaborative Studies (R34)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-MH-09-090
Type of Funding:	Grant
CFDA Numbers:	93.242
CFDA Descriptions:	Mental Health Research Grants
Current Application Deadline:	Jan 14, 2009
Original Application Deadline:	Jan 14, 2009
Posted Date:	Oct 20, 2008
Creation Date:	Oct 20, 2008
Archive Date:	Feb 14, 2009
Total Program Funding:	$2,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH...; • Interaction between ARVs and Hormones in HIV and Coinfections (R01 Clinical Trial Optional...; • Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...; • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...; • AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional); • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...; • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...; • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...